Drug Trial Radar · NCT04736186
Prevention and Treatment of Pyrrolitinib-associated Diarrhea
Last checked: Nov 19, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
470
Planned (sponsor's estimate)
Start
May 16, 2020
Primary completion
Oct 31, 2022
Study completion Apr 30, 2023
Sponsor
- Lead sponsor
- Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, patients taking pyrrolitinib alone or combined with pyrrolitinib were recruited (170 cases of secondary prevention and 300 cases of non-secondary prevention). Non-secondary prevention: Explore the recovery time of oral loperamide 4mg T.I.D. for pyrrolitinib induced diarrhea of 1-2 degrees. Secondary prevention: To explore the incidence of grade 3 and above diarrhea during c1D1-C1D22 in patients with oral loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21).
Conditions
- Breast Cancer
Interventions
LoperamideDrug
Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
Loperamide and golden bifidDrug
Patients with secondary prevention will be randomly assigned to B:Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
Loperamide and montmorillonite powderDrug
Patients with secondary prevention will be randomly assigned to D:Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- time from the first day of treatment until diarrhea returns to level 0 or baseline during the first day of treatment to the 22nd day of treatmentTime frame: From the first day of treatment to the 22nd day of treatment(about 21 days)
- The proportion of 3/4 degree diarrhea in group A From the first day of treatment to the 22nd day of treatmentTime frame: From the first day of treatment to the 22nd day of treatment(about 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TianJin Medical University Cancer Institute and Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.